Press Releases Items Per Page 102550 Year None202320222021202020192018201720162015201420132012201120102007 05.24.23 Syndax Announces Participation at Two Upcoming Investor Conferences 05.08.23 Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update 05.01.23 Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023 03.30.23 Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development 03.15.23 Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients 02.28.23 Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update 02.21.23 Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023 02.14.23 Syndax Announces Participation at Upcoming Investor Conferences 01.04.23 Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference 12.14.22 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 12.10.22 Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting 12.06.22 Syndax Announces Pricing of $150 Million Public Offering of Common Stock Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
05.08.23 Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
05.01.23 Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023
03.30.23 Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development
03.15.23 Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
02.28.23 Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
02.21.23 Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023
12.14.22 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
12.10.22 Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
